Social and physical exposome factors (e.g., nutrition, poverty, education, discrimination, abuse, infections, toxins, pollution, structural inequality) accumulate across development and adulthood, shaping biological and clinical outcomes. These exposures become biologically embedded through pathways including systemic inflammation, telomere attrition, cognitive decline, accelerated aging, and whole-body health impairments. Such processes contribute to functional decline, neuropsychiatric symptoms, subjective cognitive decline, mild cognitive impairment, and ultimately dementia. Methodological approaches—such as longitudinal designs, standardized exposome/adversity measures, brain modeling, exposome–omics integration, and probabilistic inference models are required to capture the complexity of these dynamics.

file_download Download in HQ

Related content

Article cover image showing blood samples and a hand description Article
Fluid biomarkers in Alzheimer’s disease: from detecting the pathology to understanding when it causes symptoms

Advances in blood biomarkers are transforming the diagnosis and prognosis of Alzheimer’s disease, helping to assess pathology, disease progression, and co-existing pathologies.

13.10.2026 Alzheimer’s Disease
image Image Diagram showing current and potential applications of blood-based biomarkers across the Alzheimer’s disease pathway
Current and potential applications for fluid biomarkers

Overview of how blood-based biomarkers may support screening, diagnosis, staging, prognosis, and treatment decisions across the Alzheimer’s disease continuum.

13.10.2026 Alzheimer’s Disease
image Image Flowchart illustrating a plasma biomarker testing protocol for symptomatic Alzheimer’s disease
A two-step blood-based algorithm

Overview of a plasma biomarker testing pathway for symptomatic Alzheimer’s disease, using p-tau217 and eMTBR-tau243 to guide diagnostic assessment and identify underlying pathology.

13.10.2026 Alzheimer’s Disease